Gene · 3615
IMPDH2: inosine monophosphate dehydrogenase 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IMPDH2: inosine monophosphate dehydrogenase 2. Genes, record 3615. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3615
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P12268 | Inosine-5'-monophosphate dehydrogenase 2 | 514 | 25 | Ensembl, GeneID, HGNC |
Source UniProt
Patents57
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49697 | P12268 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5384 | P12268 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4953 | P12268 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5384 | P12268 | Espacenet |
| JP 2025038035 A | 2025-03-18 | 4389 | P12268 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4953 | P12268 | Espacenet |
| US 12134655 B2 | 2024-11-05 | 4389 | P12268 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 40031 | P12268 | Espacenet |
| JP 2022530667 A | 2022-06-30 | 4389 | P12268 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 143002 | P12268 | Espacenet |
1 to 10 of 57
See all 57 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AVN-944 | CHEMBL3349001 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
| MIZORIBINE | CHEMBL245019 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
| MYCOPHENOLATE MOFETIL HYDROCHLORIDE | CHEMBL1200955 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
| MYCOPHENOLATE SODIUM | CHEMBL2106643 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
| MYCOPHENOLIC ACID | CHEMBL866 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
| THIOGUANINE | CHEMBL727 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | ChEMBL |
Trials511
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605364 | MYCOPHENOLATE MOFETIL | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07566377 | MYCOPHENOLATE MOFETIL | PHASE2 | ClinicalTrials.gov | |
| NCT07548983 | MYCOPHENOLATE MOFETIL | PHASE1 | ClinicalTrials.gov | |
| NCT07519005 | MYCOPHENOLATE MOFETIL | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07491523 | MYCOPHENOLATE MOFETIL | ClinicalTrials.gov | ||
| NCT07340463 | MYCOPHENOLATE MOFETIL | PHASE2 | ClinicalTrials.gov | |
| NCT07162038 | MYCOPHENOLATE MOFETIL | PHASE1 | ClinicalTrials.gov | |
| NCT07108530 | MYCOPHENOLATE MOFETIL | PHASE2 | ClinicalTrials.gov | |
| NCT07072585 | THIOGUANINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07059156 | MYCOPHENOLATE MOFETIL | PHASE2/PHASE3 | ClinicalTrials.gov |
1 to 10 of 511
See all 511 trialsNIH grants811
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IMPDH2 papers | Newest fiscal year |
|---|---|---|---|
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 4 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 4 | 2025 |
| U19AI135972 | SARS-CoV adaptations through a Systems Biology Lens (SYBIL) | 4 | 2025 |
| U19AI135990 | HPMI: Host Pathogen Mapping Initiative | 4 | 2025 |
| P01CA018029 | Adult Leukemia Research Center | 3 | 2025 |
| P01CA078902 | Preventing Relapse After Non-myeloablative Stem Cell Transplantation: The Final Challenge | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 3 | 2025 |
1 to 10 of 811Source NIH's project files
See all 811 nih grantsPapers1,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy. | Cancer Drug Resist | 2026 | 42729688 | PubTator, text mining | PubMed |
| Targeting IMPDH2 by Casticin attenuates psoriatic inflammation by suppressing STAT3 activation in keratinocytes. | Int Immunopharmacol | 2026 | 42567108 | PubTator, text mining | PubMed |
| MMF inhibits poxvirus infection by disrupting IMPDH2 interaction with USP5 and inducing its rod-and-ring assemblies. | Virol Sin | 2026 | 42492700 | PubTator, text mining | PubMed |
| Mitochondrial metabolism-associated biomarkers in oral lichen planus and oral squamous cell carcinoma. | Funct Integr Genomics | 2026 | 42418018 | PubTator, text mining | PubMed |
| Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP. | Mol Cell | 2026 | 42392044 | PubTator, text mining | PubMed |
| Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function. | Proc Natl Acad Sci U S A | 2026 | 42308042 | PubTator, text mining | PubMed |
| Exploring the Toxicological Impact and Mechanisms of DEHP Exposure on Prostate Cancer Through Network Toxicology and Machine Learning Algorithms. | Curr Med Chem | 2026 | 42304923 | PubTator, text mining | PubMed |
| Grape seed proanthocyanidin extract suppresses bladder cancer by dual blockade of IMPDH1/2-mediated purine and pyrimidine nucleotide biosynthesis. | J Ethnopharmacol | 2026 | 41962611 | PubTator, text mining | PubMed |
| USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer. | Cell Death Dis | 2026 | 41922317 | PubTator, text mining | PubMed |
| Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome. | Nat Commun | 2026 | 41904120 | PubTator, text mining | PubMed |
1 to 10 of 1,079
See all 1,079 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3615
GET https://conductscience.org/api/genes/v1/3615/patents?page=2